Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
Portfolio Pulse from Vandana Singh
Eli Lilly's Alzheimer's drug, donanemab, will face an FDA advisory committee vote on June 10 to assess its benefit-risk profile based on Phase 3 study data. The study showed statistically significant results in reducing cognitive decline and improving daily function in Alzheimer's patients.
June 06, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Alzheimer's drug, donanemab, will be reviewed by the FDA advisory committee on June 10. Positive Phase 3 study results could lead to approval, impacting the stock price.
The upcoming FDA advisory committee vote on donanemab is crucial for Eli Lilly. Positive Phase 3 results showing significant cognitive and functional improvements in Alzheimer's patients could lead to approval, likely boosting the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100